Sponsorship bias in clinical research

International Journal of Risk and Safety in Medicine

Volumn 24, Issue 4, 2012, Pages 233-242

  Lexchin, Joel ^a,b,c  

^a YORK UNIVERSITY   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Bias; clinical research; funding; pharmaceutical industry; sponsorship; trials

Indexed keywords

ARTICLE; CLINICAL PROTOCOL; CLINICAL RESEARCH; CONSENSUS DEVELOPMENT; DRUG INDUSTRY; KNOWLEDGE; LEGAL ASPECT; SYSTEMATIC ERROR;

BIAS (EPIDEMIOLOGY); BIOMEDICAL RESEARCH; CONFLICT OF INTEREST; DRUG INDUSTRY; HUMANS;

EID: 84872256754     PISSN: 09246479     EISSN: 18786847     Source Type: Journal    
DOI: 10.3233/JRS-2012-0574     Document Type: Article

References (42)

1. Pharmaceutical Research and Manufacturers of America. Pharmaceutical industry profile 2011.Washington DC: PhRMA; 2011.
2. National Institutes of Health. The NIH almanac - appropriations. U.S. Department of Health and Human Services; 2011.
3. Moses HI, Dorsey ER, Matheson DHM, Thier SO. Financial anatomy of biomedical research. JAMA. 2005;294:1333-42.
4. Hole OP, Winther FØ, Straume B. Clinical research: The influence of the pharmaceutical industry. Eur J Clin Pharmacol. 2001;56:851-3.
5. PatsopoulosNA, Ioannidis JPA, Analatos AA. Origin and funding of the most frequently cited papers in medicine: Dababase analysis. BMJ. 2006;332:1061-4.
6. Tallon D, Chard J, Dieppe P. Relation between agendas of the research community and the research consumer. Lancet. 2000;355:2037-40.
7. Blumenthal D, Campbell EG, Causino N, Louis KS. Participation of life-science faculty in research relationships with industry. New Engl J Med. 1996;1996(335):1734-9.
8. Blumenthal D, Gluck M, Louis KS, Stoto MA, Wise D. University-industry research relationships in biotechnology: Implications for the university. Science. 1986;232:1361-6.
9. Zinner DE, Bjankovic D, Clarridge B, Blumenthal D, Campbell EG. Participation of academic scientists in relationships with industry. Health Affairs. 2009;28:1814-25.
10. Krumholz SD, Egilman DS, Ross JS. Study of neurontin: Titrate to effect, profile of safety (STEPS) trial: A narrative account of a gabapentin seeding trial. Arch Intern Med. 2011;171:1100-7.
11. Katz KA, Karlawish JH, Chiang DS, Bognet RA, Propert KJ, Margolis DJ. Prevalence and factors associated with use of placebo control groups in randomized controlled trials in psoriasis: A cross-sectional study. Journal of the American Academy of Dermatology. 2006;55:814-22.
12. Procyshyn RM, Chau A, Fortin P, JenkinsW. Prevalence and outcomes of pharmaceutical industry-sponsored clinical trials involving clozapine, risperidone, or olanzapine. Canadian Journal of Psychiatry. 2004;49:601-6.
13. Djulbegovic B, Cantor A, Clarke M. The importance of preservation of the ethical principle of equipoise in the design of clinical trials: Relative impact of the methodological quality domains on the treatment effect in randomized controlled trials. Accountability in Research. 2003;10:301-15.
14. Psaty BM, Weiss NS, Furberg CD. Recent trials in hypertension: Compelling science or commercial speech? JAMA. 2006;295:1704-6.
15. Nieto A, Mazon A, Pamies R, Linana JJ, Lanuza A, Jim'enez FO, et al. Adverse effects of inhaled corticosteroids in funded and nonfunded studies. Arch Intern Med. 2007;167:2047-53.
16. Rochon PA, Sekeres M, Hoey J, Lexchin J, Ferris LE, Moher D, et al. Investigator experiences with financial conflicts of interest in clinical trials. Trials. 2011;12:9.
17. Mello MM, Clarridge BR, Studdert DM. Academic medical centers' standards for clinical-trial agreements wiht industry. New Engl J Med. 2005;352:2202-10.
18. Henry DA, Kerridge IH, Hill SR, McNeill PM, Doran E, Newby DA, et al. Medical specialists and pharmaceutical industry-sponsored research: A survey of the Australian experience. MJA. 2005;182:557-60.
19. DiMasi JA. Success rates for new drugs entering clinical testing in the United States. Clin Pharmacol Ther. 1995;58:1-14.
20. Psaty BM, Rennie D. Stopping medical research to save money: A broken pact with researchers and patients. JAMA. 2003;289:2128-31.
21. Trotta F, Apolone G, Garattini S, Tafuri G. Stopping a trial early in oncology: For patients or for industry? Annals of Oncology. 2008;19:1347-53.
22. Montori VM, Devereaux PJ, Adhikari NKJ, Burns KEA, Eggert CH, Briel M, et al. Randomized trials stopped early for benefit: A systematic review. JAMA. 2005;294:2203-9.
23. Psaty BM, Kronmal RA. Reporting mortality findings in trials of rofecoxib for Alzheimer Disease or cognitive impairment: A case study based on documents from rofecoxib litigation. JAMA. 2008;299:1813-7.
24. Lurie P, Wofle SM. Misleading data analyses in salmeterol (SMART) study. Lancet. 2005;366:1261-2.
25. Psaty BM, Furberg CD, Ray WA, Weiss NS. Potential for conflict of interest in the evaluation of suspected adverse drug reactions: Use of cerivastatin and risk of rhabdomyolysis. JAMA. 2004;292:2622-31.
26. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. JAMA. 2000;284:1247-55.
27. Hrachovec JB, Mora M. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib. JAMA. 2001;286:2398.
28. Wright JM, Perry TL, Bassett KL, Chambers GK. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib. JAMA. 2001;286:2398-9.
29. Gøtzsche PC, Hr'objartsson A, Johansen HK, Haahr MT, Altman DG, Chan A-W. Constraints on publication rights in industry-initiated clinical trials. JAMA. 2006;295:1645-6.
30. Jureidini J, Clothier R. Elsevier should divest itself of either its medical publishing or pharmaceutical services division. Lancet. 2009;374:375.
31. Bero LA, Galbraith A, Rennie D. The publication of sponsored symposiums in medical journals. New Engl J Med. 1992;327:1135-40.
32. Cho MK, Bero LA. The quality of drug studies published in symposium proceedings. Annals of Internal Medicine. 1996;124:485-9.
33. Rochon PA, Gurwitz JH, Cheung M, Hayes JA, Chalmers TC. Evaluating the quality of articles published in journal supplements compared with the quality of those published in the parent journal. JAMA. 1994;272:106-13.
34. Citrome L. Citability of original research and reviews in journals and their sponsored supplements. PLoS One. 2010;5:e9876.
35. Kauffman M, Julien A. Scientists helped industry to push diet drug medical research: Can we trust it? Hartford Courant. 2000 April 10.
36. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in health postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial, JAMA. 2002;288:321-33.
37. Singer N. Medical papers by ghostwriters pushed therapy. New York Times. 2009 August 5.
38. Cowley AJ, Skene A, Stainer K, Hampton Jr. The effect of lorcainide on arrhythmias and survival in patients with acute myocardial infarction: An example of publication bias. International Journal of Cardiology. 1993;40:161-6.
39. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. New Engl J Med. 1989;321:406-12.
40. Lexchin J, Bero L, Djubegovic B, Clark O. Pharmaceutical industry sponsored research: Evidence for a systematic bias. BMJ. 2003;326:1167-70.
41. Ramsey S, Scoggins J. Commentary: Practicing on the tip of an information iceberg? Evidence of underpublication of registered clinical trials in oncology. The Oncologist. 2008;13:925-9.
42. Rising K, Bacchetti P, Bero L. Reporting bias in drug trials submitted to the Food and Drug Administration: Review of publication and presentation. PLoS Medicine. 2008;5:e217.